Payer formulary tier increases of apixaban: how patients respond and potential implications

References

• Gruber J. The role of consumer copayments for health care: lessons from the RAND health insurance experiment and beyond. 2006. https://www.kff.org/wp-content/uploads/2013/01/7566.pdf.
   Google Scholar
• Dieguez G, Alston M, Tomicki S. A primer on prescription drug rebates: insights into why rebates are a target for reducing prices. 2018. https://www.milliman.com/en/insight/-/media/Milliman/importedfiles/uploadedFiles/insight/2018/prescription-drug-rebates.ashx.
   Google Scholar
• Roehrig C. The impact of prescription drug rebates on health plans and consumers. 2018. https://altarum.org/sites/default/files/Altarum-Prescription-Drug-Rebate-Report_April-2018.pdf.
   Google Scholar
• West Health-Gallup. 2021 Healthcare in America Report 2021. https://www.gallup.com/analytics/357932/healthcare-in-america-2021.aspx.
   Google Scholar
• Kyle MA, Blendon RJ, Benson JM, et al. Financial hardships of Medicare beneficiaries with serious illness. Health Aff. 2019;38(11):1801–1806. doi: 10.1377/hlthaff.2019.00362.
   Web of Science ®Google Scholar
• McInerney M, Rutledge MS, King SE. How much does health spending eat away at retirement income? 2022. https://crr.bc.edu/wp-content/uploads/2022/07/IB_22-12.pdf.
   Google Scholar
• Nekui F, Galbraith AA, Briesacher BA, et al. Cost-related medication nonadherence and its risk factors among Medicare beneficiaries. Med Care. 2021;59(1):13–21. doi: 10.1097/MLR.0000000000001458.
   PubMed Web of Science ®Google Scholar
• Madden JM, Bayapureddy S, Briesacher BA, et al. Affordability of medical care among Medicare enrollees. JAMA Health Forum. 2021;2(12):e214104. doi: 10.1001/jamahealthforum.2021.4104.
   PubMedGoogle Scholar
• 2021 Profile of older Americans. 2022. https://acl.gov/sites/default/files/Profile%20of%20OA/2021%20Profile%20of%20OA/2021ProfileOlderAmericans_508.pdf.
   Google Scholar
• Gangopadhyaya A, Holahan J, Garrett B, et al. Adding an out-of-pocket spending limit to traditional Medicare. 2022. Available from: https://www.rwjf.org/en/insights/our-research/2022/06/an-out-of-pocket-spending-cap-would-make-medicare-more-affordable-for-millions.html.
   Google Scholar
• Special advisory bulletin - pharmaceutical manufacturer copayment coupons [Internet]. Department of Health and Human Services Office of Inspector General; 2014. Available from: https://oig.hhs.gov/documents/special-advisory-bulletins/878/SAB_Copayment_Coupons.pdf.
   Google Scholar
• Deitelzweig S, Terasawa E, Kang A, et al. Payer formulary exclusions of apixaban: how patients respond and potential implications. Curr Med Res Opin. 2022;38(11):1885–1890. doi: 10.1080/03007995.2022.2128189.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Keshishian A, Kang A, et al. Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity. Adv Ther. 2021;38(6):3166–3184. doi: 10.1007/s12325-021-01724-8.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. JCM. 2020;9(6):1633. doi: 10.3390/jcm9061633.
   Web of Science ®Google Scholar
• Deitelzweig S, Keshishian A, Li X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc. 2019;67(8):1662–1671. doi: 10.1111/jgs.15956.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Keshishian AV, Zhang Y, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer. JACC CardioOncol. 2021;3(3):411–424. doi: 10.1016/j.jaccao.2021.06.004.
   PubMedGoogle Scholar
• Fralick M, Colacci M, Schneeweiss S, et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172(7):463–473. doi: 10.7326/M19-2522.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604 e11. doi: 10.1016/j.amjmed.2018.12.023.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):405–414. doi: 10.1093/ehjcvp/pvaa117.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. J Thromb Thrombolysis. 2022;54(1):33–46. doi: 10.1007/s11239-022-02660-2.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi: 10.1161/STROKEAHA.118.020232.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021;289(1):42–52. doi: 10.1111/joim.13140.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Kang AL, et al. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clin Proc. 2020;95(5):929–943. doi: 10.1016/j.mayocp.2019.05.032.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Zhang Y, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Netw Open. 2021;4(8):e2120064. doi: 10.1001/jamanetworkopen.2021.20064.
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Stein CM, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395–2404. doi: 10.1001/jama.2021.21222.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
   PubMed Web of Science ®Google Scholar
• Hoadley J, Cubanski J, Neuman T. Medicare Part D: a first look at prescription drug plans in 2017. 2016. Available from: https://files.kff.org/attachment/Issue-Brief-Medicare-Part-D-A-First-Look-at-Prescription-Drug-Plans-in-2017
   Google Scholar
• 2016 Social Security Changes Fact Sheet [Internet]. Social security administration. Available from: https://www.ssa.gov/news/press/factsheets/colafacts2016.pdf.
   Google Scholar
• 2017 Social Security Changes Fact Sheet [Internet]. Social security administration. Available from: https://www.ssa.gov/news/press/factsheets/colafacts2017.pdf.
   Google Scholar
• Heidenreich PA, Estes NAM, 3rd, Fonarow GC, et al. 2020 Update to the 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association task force on performance measures. Circ Cardiovasc Qual Outcomes. 2021;14(1):e000100.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Cea Soriano L, Munk Hald S, et al. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Heart. 2020;107(7):542–548. doi: 10.1136/heartjnl-2020-317887.
   PubMed Web of Science ®Google Scholar
• Carnicelli AP, Al-Khatib SM, Xavier D, et al. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. Heart. 2021;107(9):713–720. doi: 10.1136/heartjnl-2020-317229.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117(7):1448–1454. doi: 10.1160/TH16-12-0961.
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129(18):1850–1859. doi: 10.1161/CIRCULATIONAHA.113.005754.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi: 10.1161/CIR.0000000000000558.
   PubMed Web of Science ®Google Scholar
• Chohan SA, Venkatesh PK, How CH. Long-term complications of stroke and secondary prevention: an overview for primary care physicians. Singapore Med J. 2019;60(12):616–620. doi: 10.11622/smedj.2019158.
   PubMed Web of Science ®Google Scholar
• Whitehead S, Baalbergen E. Post-stroke rehabilitation. S Afr Med J. 2019;109(2):81–83. doi: 10.7196/SAMJ.2019.v109i2.00011.
   Web of Science ®Google Scholar
• Teo K, Slark J. A systematic review of studies investigating the care of stroke survivors in long-term care facilities. Disabil Rehabil. 2016;38(8):715–723. doi: 10.3109/09638288.2015.1059496.
   PubMed Web of Science ®Google Scholar
• Johnson BH, Bonafede MM, Watson C. Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke. Clinicoecon Outcomes Res. 2016;8:53–61. doi: 10.2147/CEOR.S95662.
   PubMed Web of Science ®Google Scholar
• Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459–1466. doi: 10.1161/01.str.27.9.1459.
   PubMed Web of Science ®Google Scholar
• Anderson CS, Jamrozik KD, Broadhurst RJ, et al. Predicting survival for 1 year among different subtypes of stroke. Results from the Perth community stroke study. Stroke. 1994;25(10):1935–1944. doi: 10.1161/01.str.25.10.1935.
   PubMed Web of Science ®Google Scholar
• Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen stroke study. Stroke. 1996;27(10):1765–1769. doi: 10.1161/01.str.27.10.1765.
   PubMed Web of Science ®Google Scholar
• Medicare 2023 Part C & D star ratings technical notes. 2022. Available from: https://www.cms.gov/files/document/2023-star-ratings-technical-notes.pdf.
   Google Scholar